MedTrace Logo

Montelukast in Acute RSV Bronchiolitis

NCT00524693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2007-09-05

No results posted yet for this study

Summary

There is evidence of inflammatory mechanisms in RSV bronchiolitis with increased cysteinyl-leukotrienes (cys-LT). Recently, specific cys-LT receptor antagonists - montelukast (Singulair©) approved for use in infants as granule sachets, have become available. We evaluated the effect of Singulair© on clinical progress and on cytokine profiles in the acute phase of RSV bronchiolitis.

Conditions

  • Bronchiolitis

Interventions

DRUG

Montelukast

4mg sachets

DRUG

Placebo granules

Sponsors & Collaborators

  • Wolfson Medical Center

    collaborator OTHER_GOV

  • Ziv Hospital

    lead OTHER_GOV

Principal Investigators

  • Israel Amirav, MD · Ziv Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
4 Weeks
Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00524693 on ClinicalTrials.gov